1. Home
  2. SRTA vs GYRE Comparison

SRTA vs GYRE Comparison

Compare SRTA & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SRTA

Strata Critical Medical Inc.

HOLD

Current Price

$5.11

Market Cap

530.4M

Sector

N/A

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.24

Market Cap

606.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRTA
GYRE
Founded
2014
2002
Country
United States
United States
Employees
601
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
530.4M
606.4M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
SRTA
GYRE
Price
$5.11
$6.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$7.81
$17.00
AVG Volume (30 Days)
1.3M
107.1K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$275,000.00
Revenue This Year
$39.27
$19.88
Revenue Next Year
$8.52
N/A
P/E Ratio
$9.88
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.85
$5.44
52 Week High
$6.50
$9.42

Technical Indicators

Market Signals
Indicator
SRTA
GYRE
Relative Strength Index (RSI) 42.35 44.86
Support Level $4.76 $5.59
Resistance Level $5.16 $8.28
Average True Range (ATR) 0.22 0.35
MACD -0.00 -0.04
Stochastic Oscillator 17.86 10.95

Price Performance

Historical Comparison
SRTA
GYRE

About SRTA Strata Critical Medical Inc.

Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: